China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million.
Carvykti’s Impact on Revenue
The BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy Carvykti, co-developed with J&J, played a pivotal role in Legend Biotech’s financial performance. Carvykti generated USD334 million in Q4 sales and USD963 million in full-year 2024 sales. This success drove Legend Bio’s cooperation income to USD168 million in Q4 and USD483 million for the full year.
Licensing Income and Production Expansion
Legend Bio recorded licensing income of USD18.3 million in Q4 and USD138.4 million for the full year, primarily from milestone payments related to Carvykti and a licensing deal with Novartis concerning LB2102 and other DLL-3-targeted CAR-T products. In the first quarter of 2025, Legend Bio initiated commercial production of Carvykti at one of Novartis’ facilities, as part of the manufacturing and supply agreement among Legend Bio, J&J, and Novartis.
Financial Position
As of December 31, 2024, Legend Bio had approximately USD1.1 billion in cash and cash equivalents, as well as term deposits. This robust financial position is expected to support the company through the second quarter of fiscal year 2026.-Fineline Info & Tech
Leave a Reply